Review article
SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?
Los iSGLT2 en la insuficiencia cardiaca. ¿Sus beneficios pueden extenderse a todo el espectro de la fracción de eyección?
Juan Antonio Requena-Ibáñez
, Carlos G. Santos-Gallego, Juan José Badimón
Corresponding author
Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York City, United States
Read
1460
Timeswas read the article
318
Total PDF
1142
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 July | 92 | 20 | 112 |
| 2024 June | 90 | 21 | 111 |
| 2024 May | 104 | 31 | 135 |
| 2024 April | 99 | 31 | 130 |
| 2024 March | 134 | 31 | 165 |
| 2024 February | 141 | 26 | 167 |
| 2024 January | 85 | 30 | 115 |
| 2023 December | 83 | 23 | 106 |
| 2023 November | 91 | 17 | 108 |
| 2023 October | 108 | 32 | 140 |
| 2023 September | 7 | 3 | 10 |
| 2023 May | 2 | 1 | 3 |
| 2023 April | 6 | 0 | 6 |
| 2023 March | 13 | 9 | 22 |
| 2023 January | 2 | 4 | 6 |
| 2022 December | 1 | 0 | 1 |
| 2022 November | 1 | 3 | 4 |
| 2022 October | 4 | 2 | 6 |
| 2022 September | 12 | 4 | 16 |
| 2022 August | 64 | 20 | 84 |
| 2022 July | 3 | 10 | 13 |
Show all
